Table 1. Tumor formation capacity of 201B7 hiPSCs in NOG mice.

Group	Tumor incidence at indicated hiPSC dose at 16 wk						TPD50	95% confidence interval for the TPD50
	0	1 × 10	1 × 102	1 × 103	1 × 104	1 × 105		Lower	Upper
hiPSC clumps	0/6a	— (0/6)b	2/6	2/6	6/6	—	681	199	2327
Single hiPSCs/NHDF	0/6	0/6	0/6	0/6	5/6	— (6/6)c	4642	2336	9223
Single hiPSCs/NHDF + Y27632	0/10	0/10	2/10	7/10	8/10	— (10/10)c	631	223	1783

—: not tested

^aNumber of mice in which tumor formed/total number of mice inoculated.

^bSince not all mice inoculated with the lowest dose (1x10²) showed the negative (non-tumor bearing) results, it was assumed that the tumor incidence of mice at an even lower dose step (a dummy set of data) would have been 0% for the Spearman-Kärber method to be applicable.

^cSince not all mice inoculated with the highest dose (1x10⁴) formed tumors, it was assumed that the tumor incidence of mice at an even higher dose step (a dummy set of data) would have been 100% for the Spearman-Kärber method to be applicable.